United States Tariff Plan Threatens Indian Pharmaceutical Export Growth Market

United States announces a phased tariff on generic medicines, starting at 0% now, rising to 100% in two years and 200% by 2029, targeting low‑cost Indian drugs entering the U.S. market for American consumers.

India reported a 6.8% rise in pharmaceutical exports in the first quarter of FY27, driven by strong demand for generics, but the looming tariffs could erode this momentum and shift buyers to alternative sources in key markets like Europe.

Pharma Exporters face additional pressure from a freight surge and Gulf region tensions that threaten ₹5,000‑crore of shipments to West Asia, prompting some firms to explore new logistics routes and markets over the next year.

Analysts warn that combined tariff and shipping challenges may push Indian manufacturers to focus on emerging markets and accelerate biosimilar development, while U.S. generic drug approvals are expected to rise, intensifying competition to sustain growth.